Joan obtained PhD in life science and license as a physician with board certification in US. She also had 3 postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She practiced as a psychiatrist and worked in Eli Lilly & Co, Wyeth and Pfizer, where she was responsible for global clinical development programs cross phase 1-4. She has extensive experiences working with FDA, EMEA, CFDA, PMDA, KFDA and etc. She holds an academic position as the adjunctive professor in Indiana University School of Medicine.

Joan was sent to China by Pfizer in 2011 as the China clinical head and joined Hengrui as the CMO in May 2013. She was granted the honor of  "Talent of Innovation" by the "National Thousand Talent Program". In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. She is also elected as the executive committee member of China New Drug Research Evaluation Committee. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Most recently Joan I-Mab biopharma as the head of R&D and is leading the efforts of China to China and China to global.